Palmar Hyperhidrosis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Palmar Hyperhidrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Palmar Hyperhidrosis: Overview
Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally. Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep. The diagnosis is usually made based on a history of excessive sweating. No investigations are needed. Treatment will depend on how severe the sweating is and which previous treatments have been successful.
'Palmar Hyperhidrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmar Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmar Hyperhidrosis Emerging Drugs
Further product details are provided in the report……..
Palmar Hyperhidrosis: Therapeutic Assessment
This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:
Palmar Hyperhidrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.
Palmar Hyperhidrosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Palmar Hyperhidrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Palmar Hyperhidrosis: Overview
Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally. Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep. The diagnosis is usually made based on a history of excessive sweating. No investigations are needed. Treatment will depend on how severe the sweating is and which previous treatments have been successful.
'Palmar Hyperhidrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmar Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Palmar Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmar Hyperhidrosis.
This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmar Hyperhidrosis Emerging Drugs
- AT-5214: Atacama Therapeutics
- Umeclidinium: GlaxoSmithKline
Further product details are provided in the report……..
Palmar Hyperhidrosis: Therapeutic Assessment
This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Palmar Hyperhidrosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Palmar Hyperhidrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.
Palmar Hyperhidrosis Report Insights
- Palmar Hyperhidrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Palmar Hyperhidrosis drugs?
- How many Palmar Hyperhidrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmar Hyperhidrosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmar Hyperhidrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Palmar Hyperhidrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Atacama Therapeutics
- GlaxoSmithKline
- Brickell Biotech, Inc.
- Candesant Biomedical
- AT-5214
- Umeclidinium
- Sofpironium bromide
Introduction
Executive Summary
Palmar Hyperhidrosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Palmar Hyperhidrosis – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
AT-5214: Atacama Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Palmar Hyperhidrosis Key Companies
Palmar Hyperhidrosis Key Products
Palmar Hyperhidrosis- Unmet Needs
Palmar Hyperhidrosis- Market Drivers and Barriers
Palmar Hyperhidrosis- Future Perspectives and Conclusion
Palmar Hyperhidrosis Analyst Views
Palmar Hyperhidrosis Key Companies
Appendix
Executive Summary
Palmar Hyperhidrosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Palmar Hyperhidrosis – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
AT-5214: Atacama Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Palmar Hyperhidrosis Key Companies
Palmar Hyperhidrosis Key Products
Palmar Hyperhidrosis- Unmet Needs
Palmar Hyperhidrosis- Market Drivers and Barriers
Palmar Hyperhidrosis- Future Perspectives and Conclusion
Palmar Hyperhidrosis Analyst Views
Palmar Hyperhidrosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Palmar Hyperhidrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Palmar Hyperhidrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Palmar Hyperhidrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Palmar Hyperhidrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
